GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr | ₹384 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹800 Cr |
| Mar2024 | ₹1,063 Cr |
| Mar2023 | ₹337 Cr |
| Mar2022 | ₹361 Cr |
| Mar2021 | ₹384 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹800 Cr | -24.74 | |
| Mar2024 | ₹1,063 Cr | 215.81 | |
| Mar2023 | ₹337 Cr | -6.81 | |
| Mar2022 | ₹361 Cr | -5.96 | |
| Mar2021 | ₹384 Cr | - | |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹62,757.0 Cr | 1.3% | 2.1% | 29% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,982.0 Cr | 0.9% | 5.6% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,361.0 Cr | 1.2% | 3.7% | -1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹164,737.0 Cr | 4.4% | 10.3% | 42.1% | Stock Analytics | |
| CIPLA | ₹115,655.0 Cr | -1.7% | 3.1% | -4.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,573.0 Cr | 0.2% | 5.7% | 6% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.3% |
2.1% |
29% |
| SENSEX | -0.5% |
3% |
-8.5% |
You may also like the below Video Courses